A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer

C. P. Li, J. S. Chen, L. T. Chen, C. J. Yen, K. D. Lee, W. P. Su, P. C. Lin, C. H. Lu, H. J. Tsai, Y. Chao

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Docetaxel plus cisplatin and 5-fluorouracil has become a new standard for treating advanced gastric cancer. However, high rates of severe neutropenia limit its application. Modification of the regimen could be the solution to get similar activity but less myelosuppression. Methods: Patients with histologically confirmed, locally advanced, or recurrent/metastatic gastric adenocarcinoma without previous chemotherapy were enrolled. This regimen consisted of docetaxel (Tyxan, TTY, Taipei, Taiwan) 30-min infusion at a dose of 36 mg m-2, followed by cisplatin 30 mg m-2 infusion over 1 h on days 1 and 8, and oral tegafur/uracil 300 mg m-2 per day plus leucovorin 90 mg per day on days 1-14, every 3 weeks. Tumour response was evaluated after every 2 cycles of treatment. Results: From August 2007 to March 2009, 45 patients were enrolled. The median age was 56 years (range: 22-75). Among the 40 patients evaluable for tumour response, one achieved a complete response, 22 had partial responses and 11 had stable disease. The overall response rates of the evaluable and intent-to-treat (ITT) populations were 58% (95% CI: 41-74%) and 53% (95% CI: 38-68%), respectively. The disease control rates in these populations were 85% (95% CI: 70-94%) and 82% (95% CI: 68-92%), respectively. In the ITT analysis, the median time to progression and overall survival were 6.8 and 13.9 months, respectively. Major grade 3-4 toxicities were neutropenia (51%), anaemia (22%), diarrhoea (16%), and infections (20%). No patient died of treatment-related toxicities. Conclusion: Concurrent weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin are effective and well tolerated in the treatment of advanced gastric cancer.

Original languageEnglish
Pages (from-to)1343-1348
Number of pages6
JournalBritish Journal of Cancer
Volume103
Issue number9
DOIs
Publication statusPublished - Oct 26 2010
Externally publishedYes

Fingerprint

docetaxel
Tegafur
Uracil
Leucovorin
Cisplatin
Stomach Neoplasms
Drug Therapy
Neutropenia
Taiwan
Fluorouracil
Population
Anemia
Diarrhea
Neoplasms
Stomach
Adenocarcinoma
Therapeutics
Survival
Infection

Keywords

  • cisplatin
  • docetaxel
  • gastric cancer
  • leucovorin
  • tegafur/uracil

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. / Li, C. P.; Chen, J. S.; Chen, L. T.; Yen, C. J.; Lee, K. D.; Su, W. P.; Lin, P. C.; Lu, C. H.; Tsai, H. J.; Chao, Y.

In: British Journal of Cancer, Vol. 103, No. 9, 26.10.2010, p. 1343-1348.

Research output: Contribution to journalArticle

Li, C. P. ; Chen, J. S. ; Chen, L. T. ; Yen, C. J. ; Lee, K. D. ; Su, W. P. ; Lin, P. C. ; Lu, C. H. ; Tsai, H. J. ; Chao, Y. / A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. In: British Journal of Cancer. 2010 ; Vol. 103, No. 9. pp. 1343-1348.
@article{1145e35d9de544169c3bd4eb27fe71cb,
title = "A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer",
abstract = "Background: Docetaxel plus cisplatin and 5-fluorouracil has become a new standard for treating advanced gastric cancer. However, high rates of severe neutropenia limit its application. Modification of the regimen could be the solution to get similar activity but less myelosuppression. Methods: Patients with histologically confirmed, locally advanced, or recurrent/metastatic gastric adenocarcinoma without previous chemotherapy were enrolled. This regimen consisted of docetaxel (Tyxan, TTY, Taipei, Taiwan) 30-min infusion at a dose of 36 mg m-2, followed by cisplatin 30 mg m-2 infusion over 1 h on days 1 and 8, and oral tegafur/uracil 300 mg m-2 per day plus leucovorin 90 mg per day on days 1-14, every 3 weeks. Tumour response was evaluated after every 2 cycles of treatment. Results: From August 2007 to March 2009, 45 patients were enrolled. The median age was 56 years (range: 22-75). Among the 40 patients evaluable for tumour response, one achieved a complete response, 22 had partial responses and 11 had stable disease. The overall response rates of the evaluable and intent-to-treat (ITT) populations were 58{\%} (95{\%} CI: 41-74{\%}) and 53{\%} (95{\%} CI: 38-68{\%}), respectively. The disease control rates in these populations were 85{\%} (95{\%} CI: 70-94{\%}) and 82{\%} (95{\%} CI: 68-92{\%}), respectively. In the ITT analysis, the median time to progression and overall survival were 6.8 and 13.9 months, respectively. Major grade 3-4 toxicities were neutropenia (51{\%}), anaemia (22{\%}), diarrhoea (16{\%}), and infections (20{\%}). No patient died of treatment-related toxicities. Conclusion: Concurrent weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin are effective and well tolerated in the treatment of advanced gastric cancer.",
keywords = "cisplatin, docetaxel, gastric cancer, leucovorin, tegafur/uracil",
author = "Li, {C. P.} and Chen, {J. S.} and Chen, {L. T.} and Yen, {C. J.} and Lee, {K. D.} and Su, {W. P.} and Lin, {P. C.} and Lu, {C. H.} and Tsai, {H. J.} and Y. Chao",
year = "2010",
month = "10",
day = "26",
doi = "10.1038/sj.bjc.6605928",
language = "English",
volume = "103",
pages = "1343--1348",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer

AU - Li, C. P.

AU - Chen, J. S.

AU - Chen, L. T.

AU - Yen, C. J.

AU - Lee, K. D.

AU - Su, W. P.

AU - Lin, P. C.

AU - Lu, C. H.

AU - Tsai, H. J.

AU - Chao, Y.

PY - 2010/10/26

Y1 - 2010/10/26

N2 - Background: Docetaxel plus cisplatin and 5-fluorouracil has become a new standard for treating advanced gastric cancer. However, high rates of severe neutropenia limit its application. Modification of the regimen could be the solution to get similar activity but less myelosuppression. Methods: Patients with histologically confirmed, locally advanced, or recurrent/metastatic gastric adenocarcinoma without previous chemotherapy were enrolled. This regimen consisted of docetaxel (Tyxan, TTY, Taipei, Taiwan) 30-min infusion at a dose of 36 mg m-2, followed by cisplatin 30 mg m-2 infusion over 1 h on days 1 and 8, and oral tegafur/uracil 300 mg m-2 per day plus leucovorin 90 mg per day on days 1-14, every 3 weeks. Tumour response was evaluated after every 2 cycles of treatment. Results: From August 2007 to March 2009, 45 patients were enrolled. The median age was 56 years (range: 22-75). Among the 40 patients evaluable for tumour response, one achieved a complete response, 22 had partial responses and 11 had stable disease. The overall response rates of the evaluable and intent-to-treat (ITT) populations were 58% (95% CI: 41-74%) and 53% (95% CI: 38-68%), respectively. The disease control rates in these populations were 85% (95% CI: 70-94%) and 82% (95% CI: 68-92%), respectively. In the ITT analysis, the median time to progression and overall survival were 6.8 and 13.9 months, respectively. Major grade 3-4 toxicities were neutropenia (51%), anaemia (22%), diarrhoea (16%), and infections (20%). No patient died of treatment-related toxicities. Conclusion: Concurrent weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin are effective and well tolerated in the treatment of advanced gastric cancer.

AB - Background: Docetaxel plus cisplatin and 5-fluorouracil has become a new standard for treating advanced gastric cancer. However, high rates of severe neutropenia limit its application. Modification of the regimen could be the solution to get similar activity but less myelosuppression. Methods: Patients with histologically confirmed, locally advanced, or recurrent/metastatic gastric adenocarcinoma without previous chemotherapy were enrolled. This regimen consisted of docetaxel (Tyxan, TTY, Taipei, Taiwan) 30-min infusion at a dose of 36 mg m-2, followed by cisplatin 30 mg m-2 infusion over 1 h on days 1 and 8, and oral tegafur/uracil 300 mg m-2 per day plus leucovorin 90 mg per day on days 1-14, every 3 weeks. Tumour response was evaluated after every 2 cycles of treatment. Results: From August 2007 to March 2009, 45 patients were enrolled. The median age was 56 years (range: 22-75). Among the 40 patients evaluable for tumour response, one achieved a complete response, 22 had partial responses and 11 had stable disease. The overall response rates of the evaluable and intent-to-treat (ITT) populations were 58% (95% CI: 41-74%) and 53% (95% CI: 38-68%), respectively. The disease control rates in these populations were 85% (95% CI: 70-94%) and 82% (95% CI: 68-92%), respectively. In the ITT analysis, the median time to progression and overall survival were 6.8 and 13.9 months, respectively. Major grade 3-4 toxicities were neutropenia (51%), anaemia (22%), diarrhoea (16%), and infections (20%). No patient died of treatment-related toxicities. Conclusion: Concurrent weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin are effective and well tolerated in the treatment of advanced gastric cancer.

KW - cisplatin

KW - docetaxel

KW - gastric cancer

KW - leucovorin

KW - tegafur/uracil

UR - http://www.scopus.com/inward/record.url?scp=78049279757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049279757&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6605928

DO - 10.1038/sj.bjc.6605928

M3 - Article

C2 - 20924378

AN - SCOPUS:78049279757

VL - 103

SP - 1343

EP - 1348

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 9

ER -